learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn oligopeptide-71
learn sh-Polypeptide-7
learn nonspecific group of glycoproteins
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 1000+ resultsresearch Human Follicular Papilla Cells Carry Out Nonadipose Tissue Production of Leptin
Leptin may play a role in hair growth and hair follicle health.
research Overview of Urethral Reconstruction by Tissue Engineering: Current Strategies, Clinical Status and Future Direction
The best method for urethral reconstruction is using hypoxia-preconditioned stem cells with autologous cells on a vascularized synthetic scaffold.
research Exploring the “Thyroid–Skin Connection”: Concepts, Questions, and Clinical Relevance
Thyroid function affects skin health, with a complex interaction between the two.
research Signaling in the stem cell niche: regulating cell fate, function and plasticity
The niche environment controls stem cell behavior and plasticity, which is important for tissue health and repair.
research ApoBDs: a paradigm shift from cellular debris to therapeutic vehicles
ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.
Community Join
5 / 1000+ resultscommunity Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.